Stockscreener 앱 받기
0.0214
0.47%
0.000100
시장 영업 전:
.02
-0.0014
-6.54%
전일 마감가:
$0.0213
열려 있는:
$0.0209
하루 거래량:
192.31M
Relative Volume:
1.83
시가총액:
$1.14M
수익:
$1.44M
순이익/손실:
$-3.21M
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-13.36%
1개월 성능:
-77.01%
6개월 성능:
-96.83%
1년 성능:
+0.00%
1일 변동 폭
$0.0197
$0.0221
1주일 범위
$0.0191
$0.0441
52주 변동 폭
$0.0161
$4.2442
Elevai Labs Inc Stock (ELAB) Company Profile
명칭
Elevai Labs Inc
전화
18667944940
주소
120 NEWPORT CENTER DRIVE, NEWPORT BEACH
ELAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ELAB | 0.0214 | 1.14M | 1.44M | -3.21M | 0 | 0.00 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Elevai Labs Inc 주식(ELAB)의 최신 뉴스
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) - Simply Wall St
CORRECTIONElevai Labs Inc. - The Bakersfield Californian
Elevai Labs Reports Mixed Q3: 74.7% Margins, Revenue Dips 4.9% Amid $8M Offering | ELAB Stock News - StockTitan
Elevai Labs Inc (ELAB) Quarterly 10-Q Report - Quartzy
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update - GlobeNewswire
Elevai Labs granted extension to meet Nasdaq listing standards - Investing.com
Elevai Labs granted extension to meet Nasdaq listing standards By Investing.com - Investing.com Canada
Natural Gas (NGN23) Quote - The Globe and Mail
Carebook Technologies Inc (CRBKF) QuotePress Release - The Globe and Mail
Fubo TV (FUBO-N) QuotePress Release - The Globe and Mail
Elevai Labs announces update and extension of pending offer to exchange shares of common stock - MSN
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire
Elevai Labs strikes new executive agreements - Investing.com India
Elevai Labs strikes new executive agreements By Investing.com - Investing.com UK
Columbia Sprtswr (COLM-Q) QuotePress Release - The Globe and Mail
Elevai Biosciences gears up for obesity drug IND submission By Investing.com - Investing.com Nigeria
Elevai Biosciences gears up for obesity drug IND submission - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., - GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - Yahoo Finance UK
Elevai reports promising preclinical obesity treatment results By Investing.com - Investing.com South Africa
Elevai reports promising preclinical obesity treatment results - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - The Manila Times
ELAB stock’s current quarter earnings estimates: What analysts predict? - US Post News
Elevai Labs Inc. Inc. (ELAB) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Metric Deep Dive: Understanding Elevai Labs Inc. (ELAB) Through its Ratios - The Dwinnex
Insider’s View: Deciphering Elevai Labs Inc. (ELAB)’s Financial Health Through Ratios - The Dwinnex
Views of Wall Street’s Leading Experts on Elevai Labs Inc. - SETE News
Elevai Labs Inc. [ELAB] is -94.09% lower this YTD. Is it still time to buy? - The DBT News
Elevai Labs Inc. (ELAB) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - The Manila Times
Elevai Labs Inc. Commences Offer to Exchange Up to - GlobeNewswire
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - The Manila Times
Elevai files patents for obesity treatment EL-22 By Investing.com - Investing.com Australia
Elevai files patents for obesity treatment EL-22 - Investing.com
This tiny skincare company is up big 💪 - RagingBull
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - StockTitan
Elevai Labs commences exosome skincare study By Investing.com - Investing.com South Africa
Elevai Labs commences exosome skincare study - Investing.com India
ELABElevai Labs, Inc. Latest Stock News & Market Updates - StockTitan
Elevai Labs begins clinical study of topical exosome product - TipRanks
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., - GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining - The Bakersfield Californian
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device - StockTitan
Check out these key findings about Elevai Labs Inc. (ELAB) - SETE News
ELAB Stock Update: Elevai Labs Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
What is ELAB’s price-to-sales ratio telling us about the company’s value? - US Post News
Elevai Labs Inc. [ELAB] Revenue clocked in at $2.47 million, down -94.95% YTD: What’s Next? - The DBT News
In the Green: Elevai Labs Inc. (ELAB) Closes at 0.09, Up/Down 3.71 from Previous Day - The Dwinnex
Elevai Labs Inc.’s Banking’s 100-Day Moving Average at 0.4636: Will the Stock Break Through? - The InvestChronicle
Biotech Alert: Searches spiking for these stocks today - TipRanks
Altium Capital Management LP Acquires New Stake in Elevai Labs I - GuruFocus.com
Elevai Labs Inc (ELAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
6.90%
자본화:
|
볼륨(24시간):